Collection
Built automatically
From across the library
Not curated by a person
High-risk Neuroblastoma
Compiled from across the library · built automatically
Educational content from recorded physician discussions — not medical advice. Always talk to your child's care team about your child's situation.
Content of this collection
Aggressive neuroblastoma resections using subadventitial dissection should not be performed by occasional pediatric oncological surgeons doing one case per year or every other year Neuroblastoma: Update Course 2014 · 22:21
Neuroblastoma: Update Course 2016
Watch →
At the 4th Annual Stay Current in Pediatric Surgery Update Course in 2016,Dr. Daniel Von Allmen, director of the division of general and thoracic surgery, Cincinnati Children's Hospital, begins the second half of this symposium with a discu
video25:42 · Sep 2018
Neuroblastoma: Update Course 2014
Watch →
Dr. Daniel Von Allmen, director of the division of general and thoracic surgery, cincinnati children's hospital, begins the second half of this symposium with a discussion of neuroblastoma. Case presentations are shared as well as panel dis
video25:59 · Nov 2018
Body composition changes likely reflect the overall impact of cancer therapy overall rather than radiation alone — Sophia Schermerhorn, Pancreas, Muscle, and Subcutaneous Fat Atrophy in Patients Undergoing Radiation for Neuroblastoma · 0:48
Pancreas, Muscle, and Subcutaneous Fat Atrophy in Patients Undergoing Radiation for Neuroblastoma
Watch →
Pradipta Debnath, Marissa Ray, Luke Pater, Alexandra O Glenn, Stephen Hartman, Elanchezhian Somasundaram, Todd Jenkins, Juan P Gurria, Katherine Somers, Andrew T Trout, Meera KotagalBackground/objectives: Radiation therapy (RT) is part of s
video1:10 · Apr 2026
The CAMK2G differentiation mechanism is not universal for all neuroblastoma cell lines and patients, and can only be explained in MYCN non-amplified cell lines and corresponding patients. — Yujie Ma, Dr. Yujie Ma - Best of the Best in Pediatric Surgery 2025 · 7:33
Dr. Yujie Ma - Best of the Best in Pediatric Surgery 2025
Watch →
Watch PAPS' Dr. Yujie Ma's presentation on “CAMK2G Promotes Neuronal Differentiation and Inhibits Migration in Neuroblastoma” at the 2025 Best of the Best in Pediatric Surgery event!
Moderators: Drs. Todd Ponsky, Dan von Allmen, and Meer
video8:08 · Mar 2025
Summaries and takeaways+ Show
The doctors in this collection+ Show
All expert statements+ Show
Expert statements from the recordings in this collection.
Pancreas, Muscle, and Subcutaneous Fat Atrophy in Patients Undergoing Radiation for Neuroblastoma
Radiation improves survival in high-risk neuroblastoma
clinicalSophia Schermerhorn0:00 ↗
This is a retrospective study of 50 children with high-risk neuroblastoma undergoing abdominal radiation therapy
clinicalSophia Schermerhorn0:13 ↗
The authors use CT and MRI body segmentation to measure pancreatic volume, subcutaneous fat, and muscle area before and after treatment
clinicalSophia Schermerhorn0:19 ↗
There was a significant decrease in pancreatic volume after radiation
clinicalSophia Schermerhorn0:27 ↗
Very few patients developed clinically apparent pancreatic insufficiency
clinicalSophia Schermerhorn0:31 ↗
Pancreatic insufficiency wasn't systematically screened for in this study
clinicalSophia Schermerhorn0:31 ↗
Follow-up may not be long enough to detect pancreatic effects, especially given the young average age of these patients
opinionSophia Schermerhorn0:31 ↗
Pancreatic dysfunction could be an under-recognized late effect
opinionSophia Schermerhorn0:43 ↗
Patients had a significant drop in weight percentile with smaller decreases in fat and muscle
clinicalSophia Schermerhorn0:48 ↗
Body composition changes likely reflect the overall impact of cancer therapy overall rather than radiation alone
opinionSophia Schermerhorn0:48 ↗
These findings highlight the importance of nutritional screening during cancer treatments
opinionSophia Schermerhorn0:48 ↗
As survival improves, understanding and screening for long-term effects is becoming just as important as curing the cancer itself
opinionSophia Schermerhorn1:03 ↗
Neuroblastoma: Update Course 2014
Survival rate for high-risk neuroblastoma patients is in the 38 to 40% range
epidemiologicalDaniel von Allmen0:42 ↗
Surgeon-reported degree of resection showed only 66% concordance with radiologist assessment of postoperative imaging in tandem transplant pilot study
clinicalDaniel von Allmen6:52 ↗
Repeat study in recent COG high-risk trial showed same 66% concordance rate between surgeon op notes and postoperative imaging, with surgeons underestimating and radiologists overcalling resection completeness
clinicalDaniel von Allmen7:33 ↗
Memorial Sloan Kettering data suggests biggest volume response of neuroblastoma tumor occurs with first two cycles of chemotherapy, with very little response after that
Host summaryDaniel von Allmen summarizing the discussion — not the host's own clinical position10:00 ↗
More chemotherapy or other agents like MIBG may make tumor more fibrotic and make subadventitial dissection more difficult
opinionDaniel von Allmen10:17 ↗
Complication rate for aggressive neuroblastoma resection is approximately 30% morbidity with mortality less than 1%
epidemiologicalDaniel von Allmen13:07 ↗
Riley Hospital study showed only survivors with stage 4 neuroblastoma were those who had primary tumor resection
clinical14:07 ↗
Sloan Kettering study suggests stage 4 neuroblastoma patients do better with primary tumor resection
Host summaryThe host summarizing the discussion — not the host's own clinical position14:27 ↗
Kylie's study showed no difference in survival based on completeness of neuroblastoma resection
Host summaryThe host summarizing the discussion — not the host's own clinical position14:33 ↗
European studies show no difference in survival based on completeness of neuroblastoma resection
Host summaryThe host summarizing the discussion — not the host's own clinical position14:35 ↗
Most recent COG study shows probably no difference in survival based on completeness of neuroblastoma resection
Host summaryThe host summarizing the discussion — not the host's own clinical position14:35 ↗
High-risk neuroblastoma patients receive 9 different drugs, bone marrow transplantation, and some receive total body radiation
clinical14:55 ↗
High-risk neuroblastoma treatment includes tandem peripheral blood stem cell transplants, with second transplant given as soon as patient recovers from first, followed by immunotherapy and Retin-A
clinicalDaniel von Allmen15:10 ↗
High-risk neuroblastoma survival increased from 10% to 30-40% with treatment intensification
epidemiological16:01 ↗
Georgia study showed 46% survival in high-risk neuroblastoma with transplantation plus immunotherapy plus differentiating agents
Host summaryThe host summarizing the discussion — not the host's own clinical position16:22 ↗
Many deaths in intensified high-risk neuroblastoma treatment were due to the treatment itself rather than cancer
Host summaryThe host summarizing the discussion — not the host's own clinical position16:22 ↗
German study of 278 stage 4 high-risk neuroblastoma patients achieved complete resection in almost half and >90% resection in another quarter (75% total with >90% resection)
Host summaryDaniel von Allmen summarizing the discussion — not the host's own clinical position16:48 ↗
German study showed overall survival 45%, event-free survival 33%, and local progression-free survival 58% in stage 4 neuroblastoma
Host summaryDaniel von Allmen summarizing the discussion — not the host's own clinical position17:13 ↗
What's new+ Show